FMT restores gut microbiota balance by transferring stool from healthy donors, mainly for recurrent C. difficile infections. Recent data shows FMT's high efficacy in preventing recurrent C. difficile, ...

Panelist discusses how recurrent Clostridioides difficile infection results from persistent microbiome disruption, where antibiotic-induced dysbiosis enables bacterial overgrowth and toxin production.

A study, published in Infection Control & Hospital Epidemiology, examined the factors associated with first Clostridium difficile infection that predict the use of fecal microbiota transplantation for ...

The MarketWatch News Department was not involved in the creation of this content. -- Results from two real-world studies, presented at IDWeek 2025, include initial registry findings and highlight ...

Researchers may not yet understand the mechanism behind recurrent Clostridium difficile infections, but they may have isolated five risk factors, according to a study published in Infection Control & ...

WASHINGTON -- Extended follow-up of a phase III trial demonstrated continued benefit for an investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infections.

Results from a Phase 1b/2 trial suggest that an investigational microbiome-based, oral therapeutic drug is effective for the treatment of recurrent C. difficile infection. In a paper published online ...

SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

Please provide your email address to receive an email when new articles are posted on . During his presentation, Sahil Khanna, MBBS, MS, professor of medicine at the Mayo Clinic in Rochester, ...

Two gastroenterologists spoke with Becker’s to discuss research challenges, advice for early-career physicians and more. Paul Feuerstadt, MD, is a practicing gastroenterologist at the ...

Please provide your email address to receive an email when new articles are posted on . In this video, C. Jonathan D. Foster, DO, FACOI, discusses results from the PRISM3 trial assessing CP101, an ...

Intestinal infection with the bacterium Clostridium difficile is the most frequent healthcare-linked infection in the United States. Each year it afflicts about half a million Americans, causes tens ...